Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis

Seok-Hwan Kim, Sunhee Jang, Yegyu Sung, Jun Kyu Park, Yunjung Park, Jintak Yun and Sang-Bum Kang

INTRODUCTION

Crohn’s disease (CD) and ulcerative colitis (UC) are the two major types of inflammatory bowel disease, which affect the gastrointestinal tract and can also exhibit extraintestinal involvement, such as arterial and venous thromboembolism. Although arterial and venous thromboembolism can be devastating to IBD patients, they are frequently overlooked by physicians. The mainstay of therapy for thromboembolism is anticoagulation, and vitamin K antagonists (VKAs) are frequently used as the standard treatment. The recently developed novel oral anticoagulants (NOACs) may replace VKAs in thromboembolic treatment. However, no report of treatment of UC with thromboembolism using NOACs has been reported to date, and treatment guidelines have not been established. We report here a case of a patient with severe acute UC, deep vein thrombosis and pulmonary thromboembolism, together with cytomegalovirus colitis, who was successfully treated using the NOAC rivaroxaban.
CASE REPORT

A 42-year-old female patient presented to the clinic with complaints of fever and chest discomfort of 1-week duration. She had been diagnosed with UC pancolitis 4 years prior and treated with oral mesalamine and episodic oral steroid. Recently, she had experienced a disease flare-up, stool frequency more than 10 times per day with rectal bleeding, and received infliximab as an induction therapy at another hospital. This treatment did not control her rectal bleeding, abdominal pain or fever; moreover, the patient developed new symptoms, such as left calf pain and chest discomfort, 1 week prior to visiting our clinic. She did not have any diseases other than UC, and was neither a smoker nor an alcohol drinker.

An initial physical examination showed dull lower abdominal pain, left calf swelling with pain, and chest discomfort without signs of dyspnea. Her systolic and diastolic blood pressure was 100/60 mmHg with heart rate of 136 beats per minute. The body temperature was 38.0°C. Laboratory examination revealed anemia (hemoglobin 9.2 g/dL, hematocrit 29.2%) and elevated ESR (106 mm/hr), C-reactive protein (10.56 mg/dL) and d-dimer (5.85 μg FEU/mL) levels. Blood gas analysis showed pH 7.5, pCO₂ 38 mmHg, pO₂ 92 mmHg, HCO₃ 29.6 mmol/L, and O₂ saturation 98%. Fecal calprotectin level was more than 400 mg/kg, Factor V Leiden, lupus antibody, antiphospholipid antibody, anticardiolipin antibody, protein C and S activity, homocysteine and complement levels were within the normal range.

Initial sigmoidoscopy revealed multiple longitudinal ulcerations with a friable mucosa and easy touch bleeding in all colonic fields (Fig. 1). Random biopsies and tissue cytomegalovirus (CMV) polymerase chain reaction (PCR) were performed. The results indicated acute and chronic colitis, to-
Fig. 2. Chest dynamic computed tomography showed a filling defect in the lobar and segmental branches of the right pulmonary artery (arrows). (A, B) Transverse. (C, D) Coronal view.

Fig. 3. Lower extremity computed tomography showed diffuse filling defect from the left common iliac vein to the calf veins of the lower left leg (arrows), and normal vessels of the lower right leg (arrowhead). (A) Iliac crest level. (B) Symphysis pubis level. (C) Popliteal level.

together with negative CMV immunohistochemistry, but positive CMV PCR. CMV IgG was positive and CMV real-time PCR using whole blood yielded a viral load of 633 copies/mL (19,900 IU/mL). The patient had a Mayo score of 12 points.

Initial chest dynamic computed tomography (CT) and lower-extremity CT showed diffuse deep vein thrombosis from
the left common iliac vein to the calf veins of the lower left leg and filling defects in the lobar and segmental branches of the right lung, suggesting pulmonary thromboembolism (Fig. 2, 3). We started oral mesalamine and azathioprine and intravenous hydrocortisone and then switched to oral prednisolone as management for severe acute UC. Ganciclovir 5 mg/kg bid was administered for CMV colitis, and low-molecular-weight heparin for 2 weeks was given for pulmonary thromboembolism, followed by a switch to oral rivaroxaban. There are many data supporting the efficacy in patient treated with NOACs in pulmonary thromboembolism. Moreover, her veins were very vulnerable, drawing blood and giving injections have caused her a great physical and psychological trauma. For these reasons, we have decided to use oral rivaroxaban rather than conventional anticoagulation with VKAs, which does not have to draw blood every time to check the target international normalized ratio (INR) level. After 6 weeks, infliximab was administered as a third induction dose. After treatment initiation, the hematochezia ceased on day 17 of hospitalization, and the stool frequency decreased to three times per day on day 39 of hospitalization. Her Mayo score had decreased to 9 points at the time of discharge.

For the pulmonary thromboembolism, chest discomfort subsided on day 3 of hospitalization, and the left leg swelling and pain subsided on day 6 of hospitalization. The patient was discharged on day 40 of hospitalization without complications. After rivaroxaban treatment for 2 months, a follow-up chest CT was performed (Fig. 4). The previously noted pulmonary embolism at the lobar and segmental pulmonary arteries of the right lung had disappeared. The patient was maintained

Fig. 4. Follow up chest computed tomography after 2 months of rivaroxaban treatment. The previously noted filling defect in the lobar and segmental branches of the right pulmonary artery had disappeared. (A, B) Transverse view. (C, D) Coronal view.
on anticoagulation therapy with oral rivaroxaban for 6 months. She regularly visited the clinic after cessation of anticoagulation treatment for 6 months and maintained deep remission with infliximab and oral azathioprine.

**DISCUSSION**

Deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE) are important extraintestinal complications of IBD. In comparison with healthy individuals, patients with UC and CD show a threefold higher incidence of thrombosis, and up to a 16-fold increase during disease flare-ups. A study in an Asian population reported 1.98- and 1.80-fold increases in the incidence of DVT and PTE, respectively. In the general population, the 30-day case fatality rates of DVT and PTE are 11-30%, and these data also correlate with IBD patients which can be life threatening. Therefore, prompt management is necessary to reduce the morbidity and mortality of these patients. Thromboembolism is caused by changes in the composition of the blood, stasis of the blood, and changes in the vessel wall, as postulated by Virchow. In IBD patients, localized and systemic inflammation can activate the coagulation cascade, resulting in increased levels of coagulation factors (such as fibrinogen, thrombocytes, factor V, and factor VIII) and decreased levels of inhibitors of blood clotting activation (such as antithrombin and protein C and S). These changes promote hypercoagulability in IBD patients, which in turn increases the risk of DVT and PTE.

An association between CMV infection and thromboembolism has been reported in immunocompromised patients, particularly those infected with human immunodeficiency virus or who have undergone transplantation. Other studies have shown a similar relationship in immunocompetent patients. Atzmony et al. reported that 6.4% of patients with acute CMV infection develop thrombosis, irrespective of other risk factors of thrombotic events, while Schimanski et al. reported a higher rate of 9.1%. These findings suggest that CMV infection itself may increase the risk of thromboembolic events. Our patient did not have predisposing factors for thromboembolism other than UC, and the CMV infection could have induced the flare-up, increasing the risk of thromboembolism. Indeed, the infection itself might enhance the risk. It is thus important to identify CMV coinfection in IBD patients who show flare-up or thromboembolic complications.

Conventionally, VKAs have been used to treat DVT and PTE. VKAs are effective for preventing recurrent venous thromboembolism, as evidenced by an 85% decrease in the relative risk. However, VKAs increase the risk of major bleeding events by 1.6-2.6% and the case-fatality rate by 11.0% during the 6 months of venous thromboembolism treatment. Therefore, the INR should be monitored. Use of NOACs abolishes the need to monitor the INR, with similar efficacy and a lower incidence of bleeding complications. The patient’s body mass index was 14.0 and her peripheral veins were very vulnerable that every time we gave injections or took blood samples, the patient suffered great pain. The use of rivaroxaban in place of conventional treatment with VKAs yielded an excellent outcome with no complications, and the decreased frequency of blood draws satisfied the patient.

Many cases of pulmonary thromboembolism in IBD patients have been reported, but none has involved the use of NOACs, with the exception of one case of cerebral venous thrombosis in CD. Our patient was treated with rivaroxaban for 6 months and did not experience recurrence during that time. We believe that in the near future, NOACs should replace VKAs for treatment of thrombotic complications in IBD patients.
365-981-992.